Hadean Ventures
Hadean Ventures
Hadean Ventures

    @hadeanventures

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • Current companies
  • Exited companies
  • News
  • ARTHEX BIOTECH

    by @hadeanventures on May 11, 2023

    Arthex Biotech is a Spanish biopharmaceutical company developing advanced RNA treatments...

    Continue Reading
  • ARTHEx Biotech Announces Closing of €42 M Series B Financing

    by @hadeanventures on May 3, 2023

    ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel…

    Continue Reading
  • COMPLEMENT THERAPEUTICS

    by @hadeanventures on April 26, 2023

    Complement Therapeutics GmbH is a German headquartered biotechnology company...

    Continue Reading
  • Complement Therapeutics Secures €72 Million in Series A Financing

    by @hadeanventures on April 17, 2023

    Complement Therapeutics Secures €72 Million in Series A Financing...

    Continue Reading
  • Alex Therapeutics extends financing round to €4.75M with leading life science VC

    by @hadeanventures on March 5, 2023

    Innovestor Life Science, a leading biotech and digital health VC, invests €1.25M in the digital…

    Continue Reading
  • Alex Therapeutics and Vicore Pharma today announce the first study subject enrolled in the pivotal study COMPANION evaluating Almee™

    by @hadeanventures on December 6, 2022

    Stockholm, 5th December 2022 — Alex Therapeutics and Vicore Pharma today announce the first study…

    Continue Reading
  • Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas

    by @hadeanventures on October 24, 2022

    Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in…

    Continue Reading
  • Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

    by @hadeanventures on October 21, 2022

    Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a…

    Continue Reading
  • Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

    by @hadeanventures on October 14, 2022

    The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex…

    Continue Reading
  • Cardior Announces First Patient Dosed in Phase 2 Study

    by @hadeanventures on July 27, 2022

    Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding…

    Continue Reading
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • 7
  • 8
  • →
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • ESG / IMPACT
  • EVENTS
  • CONTACT

What are you looking for?